Raymond James & Associates Nex Immune, Inc. Transaction History

Raymond James & Associates

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 Apr 14, 2023	BUY	$0.3 - $0.6 $87,000 - $174,000	290,000 Added 947.03%	320,622 $121,000
Q2 2022 Aug 12, 2022	BUY	$1.61 - $4.68 $16,100 - $46,800	10,000 Added 48.49%	30,622 $49,000
Q1 2022 May 11, 2022	BUY	$1.79 - $4.65 $36,913 - $95,892	20,622 New	20,622 $87,000
Q4 2021 Feb 08, 2022	SELL	$4.11 - $15.13 $106,683 - $392,729	-25,957 Closed	0 $0
Q3 2021 Nov 02, 2021	BUY	$10.32 - $16.9 $267,876 - $438,673	25,957 New	25,957 $393,000

Ticker NEXI
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 24,155,600
Market Cap $7.25M
Description
NexImmune, Inc., a clinical-stage biotechnology company, engages in developing therapies with curative potential for patients with cancer and other life-threatening immune-mediated diseases. It develops approaches to T cell immunotherapies based on its proprietary Artificial Immune Modulation, a nanoparticle technology platform. The company's pr...

Get notified when there are updates to the investment portfolio of Raymond James & Associates, based on Form 13F filings with the SEC.

Stay updated on Raymond James & Associates with notifications on news.